Deutetrabenazine Market

Deutetrabenazine Market Size, Share & Industry Analysis, By Source Pharmaceutical Manufacturers (Branded & Generic), Contract Manufacturing Organizations (CMOs), Research-Grade Suppliers, By End-User (Pharmaceutical Industry, Hospitals & Clinics, Research Institutions) and Forecast, 2025-2035

The Deutetrabenazine market is witnessing strong growth, driven by increasing demand for advanced therapies in the treatment of neurological movement disorders such as Huntington’s disease-associated chorea and Tardive Dyskinesia (TD). Deutetrabenazine, marketed under the brand name Austedo, is a vesicular monoamine transporter 2 (VMAT2) inhibitor, notable for being the first deuterated drug approved by the U.S. FDA (in 2017). The deuteration technology slows the drug’s metabolism, offering better tolerability and a more favorable dosing regimen compared to its predecessor, tetrabenazine.

As of 2024, the global Deutetrabenazine market is estimated to be valued at USD 650 million and is expected to reach USD 1.7 billion by 2035, registering a CAGR of 10.2%. Rising prevalence of TD among patients on long-term antipsychotics, increasing awareness about movement disorders, and expanding indications under clinical trials are key drivers of this market.

North America: Dominates the global market, led by the U.S., where Teva’s Austedo enjoys exclusivity and strong physician preference. The region’s robust healthcare infrastructure and growing patient awareness about movement disorders contribute to sustained growth.

Asia-Pacific: Expected to witness high growth, particularly in Japan, South Korea, and Australia, due to rising psychiatric treatment rates and increasing diagnoses of TD and Huntington’s chorea.

Latin America & Middle East: Growing markets for Deutetrabenazine, particularly where neurological disorder diagnosis and treatment infrastructure is developing. Brazil and the UAE are key focus countries for market penetration.

Seeking Comprehensive Intelligence on Different markets? Get in Touch with our Experts

Report Scope & Segmentation

  1. Introduction
  • Overview of Deutetrabenazine
  • Key Applications & Industry Use Cases
  • Market Scope & Study Objectives
  1. Market Overview
  • Global Market Size & Growth Trends (Historical & Forecast)
  • Market Value & Revenue Analysis
  • Demand-Supply Dynamics
  1. Segmental Outlook
  • By Source
    • Pharmaceutical Manufacturers (Branded & Generic)
    • Contract Manufacturing Organizations (CMOs)
    • Research-Grade Suppliers
  • Key End-Use Industries
    • Pharmaceutical Industry.
    • Hospitals & Clinics.
    • Research Institutions.
  1. Price Analysis
  • Current Price Trends (Per kg & Per Ton)
  • Price Fluctuation Factors (Raw Material Costs, Production, Trade Tariffs)
  • Regional Price Comparison (North America, Europe, Asia-Pacific, and Other)
  1. Production & Supply Volume
  • Global Production Capacity & Key Manufacturers
  • Production Process & Technological Developments
  • Raw Material Analysis
  1. Trade Analysis (Import & Export)
  • Major Exporting & Importing Countries
  • Trade Volume & Value Statistics
  • Impact of Trade Regulations & Policies
  1. Regional Analysis
  • North America (US and Canada)
  • Europe (UK, Germany, France, Italy, Spain, and Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea, Taiwan, India, and Rest of Asia-Pacific)
  • Rest of the World (Latin America Middle East and Africa)
  1. Competitive Landscape
  • Top Global Manufacturers & Market Share
  • Company Profiles & Key Developments
  • Mergers, Acquisitions & Investments
  1. Regulatory & Compliance Factors
  • FDA, REACH, and Other Regulatory Frameworks
  • Environmental & Safety Considerations
  • Emerging Policies Impacting Market Growth
  1. Conclusion & Strategic Recommendations
  • Key Takeaways for Stakeholders
  • Market Entry Strategies
$1800/- Single User License
$3600/- Multi User License

How can we help you?

Reach out to discuss how our team can help your business achieve real results.